CSL, Alentis Therapeutics Partner On Lixudebart In Deal Worth Up To $1.6 Bln
(RTTNews) - CSL (CSL.AX) and Alentis Therapeutics have entered into an exclusive global collaboration and co-promotion agreement to advance lixudebart, a potential first-in-class therapy targeting claudin-1 for the treatment of rare kidney, liver and other diseases, CSL said in a
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.